Advertisement
Full length article| Volume 81, ISSUE 4, SUPPLEMENT 2, 49-59, October 24, 1986

Famotidine in the therapy of gastric hypersecretory states

DOI:https://doi.org/10.1016/0002-9343(86)90600-5
Famotidine in the therapy of gastric hypersecretory states
Previous ArticleEconomic and health aspects of peptic ulcer disease and H2-receptor antagonists
Next ArticleComparison of effects of oral and intravenous famotidine on inhibition of nocturnal gastric acid secretion
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      The histamine (H2)-receptor antagonist famotidine was compared with ranitidine and cimetidine in its ability to control gastric acid hypersecretion in 33 patients with gastric hypersecretory states (32 patients with Zollinger-Ellison syndrome and one patient with idiopathic hypersecretion). Equipotent doses of each drug were determined in nine patients and used to determine relative onset of action, duration of action, and potency. Each drug had a similar time course of onset with a maximal effect at three to four hours after oral ingestion. The duration of action of famotidine was 30 percent longer than that of either cimetidine or ranitidine. In terms of relative potency, famotidine was nine times more potent than ranitidine and 32 times more potent than cimetidine. Thirty-two patients underwent long-term famotidine treatment for up to 34 months (mean, 10 months) with a duration in 21 patients of at least six months, in nine patients of at least 12 months, and in six patients of at least 24 months. The mean daily maintenance dose with famotidine was 0.33 g per day (range, 0.05 to 0.8 g). Prior to famotidine therapy, 27 patients were taking ranitidine and the mean daily dose required was 2.3 g per day (range, 0.6 to 5.4 g), whereas six patients were taking cimetidine and the mean daily dose was 4.6 g per day (range, 1.2 to 9.0 g). Fourteen of the 32 patients required an anticholinergic agent in addition to ranitidine or cimetidine to maintain control, whereas only five patients required an anticholinergic agent with famotidine. Gastric acid hypersecretion was controlled in seven patients with less frequent dosing with famotidine than with cimetidine or ranitidine. Long-term treatment with famotidine was not associated with any hematologic or biochemical toxicity or clinical side effects. These results demonstrate that famotidine has a similar onset of action to other H2-receptor antagonists but has a 30 percent longer duration of action and is nine times more potent than ranitidine and 32 times more potent than cimetidine. Famotidine is safe and highly effective in the long-term treatment of gastric hypersecretory states.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Jensen RT
        • Gardner JD
        • Raufman J-P
        • Pandol SJ
        • Doppman JL
        • Collen MJ
        Zollinger-Ellison syndrome.
        in: NIH combined clinical staff conference (Jensen, RT, moderator). Ann Intern Med. 98. 1983: 59-75
        • McCarthy DM
        • Olinger EJ
        • May RJ
        • Long BW
        • Gardner JD
        H2-histamine receptor blocking agents in the Zollinger-Ellison syndrome.
        Ann Intern Med. 1977; 87: 668-675
        • Malagelada JR
        • Edis AJ
        • Adson MA
        • Von Heerden JA
        • Go VLW
        Medical and surgical options in the management of patients with gastrinoma.
        Gastroenterology. 1983; 84: 1524-1532
        • Jensen RT
        • Doppman JL
        • Gardner JD
        Gastrinoma.
        in: Brooks FP Dimagno EP Gardner JD Lebenthal E Scheele GA The exocrine pancreas: biology, pathobiology and diseases. Raven Press, New York1986: 727-745
        • Jensen RT
        • Pandol SJ
        • Collen MJ
        • Raufman J-P
        • Gardner JD
        Diagnosis and management of the Zollinger-Ellison syndrome: receptors and the upper GI tract.
        J Clin Gastroenterol. 1983; 5: 123-131
        • Jensen RT
        Basis for failure of cimetidine in patients with Zollinger-Ellison syndrome.
        Dig Dis Sci. 1984; 29: 363-366
        • Collen MJ
        • Howard JM
        • McArthur KE
        • et al.
        Comparison of ranitidine and cimetidine in the treatment of gastric hypersecretion.
        Ann Intern Med. 1984; 100: 52-58
        • Jensen RT
        • Collen MJ
        • McArthur KE
        • et al.
        Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states.
        in: Misiewicz JJ Wood JR Ranitidine: therapeutic advances-1984. Excerpta Medica, Amsterdam1984: 168-198
        • Richardson CT
        • Peters MN
        • Feldman M
        • et al.
        Treatment of Zollinger-Ellison syndrome with exploratory laparotomy, proximal gastric vagotomy and H2-receptor antagonists.
        Gastroenterology. 1985; 89: 357-367
        • Takagi T
        • Takeda M
        • Maeno H
        Effect of a new potent H2-blocker. 3-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio]-N2-sulfamoylpropionamidine] (YM-11170) on gastric secretion induced by histamine and food in conscious dogs.
        Arch Int Pharmacodyn. 1982; 256: 49-58
        • Tomioka K
        • Yamada T
        Effects of histamine H2-receptor agonists and antagonists on isolated guinea-pig airway muscles.
        Arch Int Pharmacodyn. 1982; 255: 16-26
        • Takeda M
        • Takagi T
        • Yashima Y
        • Maeno H
        Effect of a new potent H2-blocker, 3-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio]-N2-sulfamoylpropionamidine (YM-11170), on gastric secretion, ulcer formation and weight of male accessory sex organs in rats.
        Arzneimittelforsch. 1982; 32: 734-737
        • Harada M
        • Terai M
        • Maeno H
        Effect of a new potent H2-receptor antagonist 3-[[[2-[(diaminomethylene)amino]-4-thiazolyl]-methyl]thio]-N2-sulfamoylpropionamidine] (YM-11170) on gastric mucosal histamine-sensitive adenylate cyclase from guinea pig.
        Biochem Pharmacol. 1983; 32: 1635-1640
        • Takeda M
        • Takagi T
        • Maeno H
        Kinetics of antisecretory action of a new H2-antagonist, YM-11170, in conscious dogs.
        Eur J Pharmacol. 1983; 91: 371-376
        • Pendleton RG
        • Torchiana ML
        • Chung C
        • et al.
        Studies on MK208 (YM-11170), a new, slowly dissociable H2-receptor antagonist.
        Arch Int Pharmacodyn Ther. 1983; 266: 4-16
        • Gajtkowski GA
        • Norris DB
        • Rising TJ
        • Wood TP
        Specific binding of 3H-tiotidine to histamine H2 receptors in guinea pig cerebral cortex.
        Nature. 1983; 304: 65-67
        • Miwa M
        • Senoue I
        • Nomiyami T
        • et al.
        The newest H2-receptor antagonist. YM-11170.
        Scand J Gastroenterol. 1982; 17: 107
        • Smith JL
        • Gamal M
        • Chremos AN
        • Graham DY
        Effect of an H2-receptor antagonist, MK-208, on gastric parietal and nonparietal secretion (abstr).
        Gastroenterology. 1983; 84: 1314

      19. Merck, Sharp and Dohme Research Laboratories: MK 208 (L643, 341/YM 11170). Summary of preclinical evaluation, on file.

        • Dammann HG
        • Muller P
        • Simon B
        Twenty-four-hour intragastric acidity and single night-time dose of three H2-blockers.
        Lancet. 1983; II: 1078
        • Howard JM
        • Collen MJ
        • Cherner JA
        • et al.
        Famotidine: an effective H2-antagonist for the therapy of Zollinger-Ellison syndrome (ZES).
        Gastroenterology. 1985; 88: 1026-1033
        • Howard JM
        • Chremos AN
        • Cornelius MJ
        • et al.
        Famotidin beim Zollinger-Ellison-Syndrom.
        in: Simon B Bianchi-Porro G Dammann HG Famotidin. Georz Thieme Verlag, Stuttgart1986: 82-94
        • McCarthy DM
        • Hyman PE
        Effect of isopropamide on response to oral cimetidine in patients with Zollinger-Ellison syndrome.
        Dig Dis Sci. 1982; 27: 353-359
        • Raufman JP
        • Collins SM
        • Pandol SJ
        • et al.
        Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome.
        Gastroenterology. 1983; 84: 108-113
        • McCallum RW
        • Kuljian B
        • Chremos AN
        • Tupy-Visich MA
        • Huber PB
        Prolonged gastric antisecretory effect of a novel H2-receptor inhibitor, MK-208 (abstr).
        Gastroenterology. 1983; 84: 1245
        • Richardson CT
        • Walsh JH
        The value of a histamine H2-receptor antagonist in the management of patients with the ZollingerEllison syndrome.
        N Engl J Med. 1976; 294: 133-135
        • Feldman M
        • Richardson CT
        • Petersen WL
        • Walsh JH
        • Fordtran JS
        Effect of low-dose propantheline on food-stimulated gastric acid secretion.
        N Engl J Med. 1977; 297: 1427-1430
        • Mignon M
        • Vallot T
        • Hervoir P
        • Benfredj P
        • Bonfils S
        Ranitidine versus cimetidine in the management of Zollinger-Ellison syndrome.
        in: Riley AJ Salmon RP Ranitidine: proceedings of the international symposium held in the context of the Seventh World Congress of Gastroenterology. Excerpta Medica, Amsterdam, Oxford, Princeton1982: 169-177
        • Jensen RT
        • Collen MJ
        • Pandol SJ
        • et al.
        Cimetidine-induced impotence and breast changes in patients with gastric hypersecretory states.
        N Engl J Med. 1983; 308: 883-887
        • Brittain RT
        • Daly MJ
        • Jack D
        • Martin LE
        • Stables R
        • Sutherland M
        The outline of the animal pharmacology of ranitidine.
        in: Misiewicz JJ Wormsley KJ The clinical use of ranitidine. Medicine Publishing Foundation, Oxford1982: 1-10
        • Liang T
        Absence of androgen receptor affinity for MK-208, a new H2-receptor antagonist (abstr).
        Clin Res. 1984; 32: 283A
        • Pearce P
        • Funder JW
        Histamine H2-receptor antagonist.
        Clin Exp Pharmacol Physiol. 1980; 7: 442
        • Edwards CR
        • Riley AJ
        The endocrine effects of ranitidine: comparison with cimetidine.
        in: Misiewicz JJ Wormsley KJ The clinical use of ranitidine. Medicine Publishing Foundation, Oxford1982: 65-69
        • Funder JW
        • Mercer JE
        Cimetidine, a histamine H2-receptor antagonist occupies androgen receptors.
        J Clin Endocrinol Metab. 1979; 48: 189-191
        • Klotz UM
        • Pasawen M
        • Arvela PA
        The H2-receptor antagonist does not affect the action and pharmacokinetics of diazepam and procainamide.
        Nauyn-Schmiedeberg's Arch Pharmacol. 1985; 329: R102
        • Powell JR
        • Dunn KH
        Histamine H2-receptor antagonists drug interaction in perspective.
        Am J Med. 1984; 77: 57-84
        • Reimann IW
        • Klotz U
        Wechselwirkungen Zwischen H2-Blockern and Anderen Pharmaka in Famotidin Georg thieme verlag.
        in: 1986: 22-48 (Stuttgart)
        • McArthur KE
        • Collen MJ
        • Cherner JA
        • Howard JM
        • Maton PN
        • Jensen RT
        • Gardner JD
        Omeprazole: effective, convenient therapy for Zollinger-Ellison syndrome.
        Gastroenterology. 1985; 88: 939-944
        • Lamers CBH
        • Lind T
        • Moberg S
        • Jansen J
        • Olbe L
        Omeprazole in Zollinger-Ellison syndrome.
        in: Effects of a single dose and a long-term treatment in patients resistant to histamine H2-receptor antagonists. N Engl J Med. 310. 1984: 748-761

      Article Info

      Identification

      DOI: https://doi.org/10.1016/0002-9343(86)90600-5

      Copyright

      © 1986 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2022 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX